TY - JOUR
T1 - Current management of hepatobiliary malignancies between centers with or without a liver transplant program
T2 - A multi-society national survey
AU - Serenari, Matteo
AU - Angelico, Roberta
AU - Lai, Quirino
AU - Patrono, Damiano
AU - Scalera, Irene
AU - Kauffmann, Emanuele
AU - Pagano, Duilio
AU - De Carlis, Riccardo
AU - Gringeri, Enrico
AU - Vitale, Alessandro
AU - AICEP-SITO-CCTF study group
N1 - nicht zu werten, nur study group member
PY - 2025/2
Y1 - 2025/2
N2 - BACKGROUND: Availability of liver transplantation (LT) as a treatment for hepatocellular carcinoma (HCC) and other liver malignancies may determine heterogeneity of therapeutic strategies across different centers.AIMS: To investigate the practice between hepato-biliary centers without (HB centers) and with a LT program (LT centers), we launched a 38-item web-based national survey, with directors of centers as a target.METHODS: The survey, including 4 clinical vignettes, collected data on their approach to HCC and transplant oncology.RESULTS: After duplicates removal, 75 respondents were considered. Respondents from LT centers (n = 22, 29.3 %) were more in favor of LT in the case of HCC outside Milan criteria (90.9 % vs. 67.9 %, p = 0.037), recurrent HCC (95.5 % vs. 50.9 %, p = 0.002) and other malignancies such as cholangiocarcinoma or neuroendocrine tumors. No significant difference was observed concerning the proportion of centers favorable to LT for unresectable colorectal liver metastases (100 % vs. 88.7 %, p = 0.100).CONCLUSION: This national survey showed how management of HCC and awareness of transplant oncology may differ between HB and LT centers. Effective networking between HB and LT centers is crucial to provide optimal treatment and access to LT.
AB - BACKGROUND: Availability of liver transplantation (LT) as a treatment for hepatocellular carcinoma (HCC) and other liver malignancies may determine heterogeneity of therapeutic strategies across different centers.AIMS: To investigate the practice between hepato-biliary centers without (HB centers) and with a LT program (LT centers), we launched a 38-item web-based national survey, with directors of centers as a target.METHODS: The survey, including 4 clinical vignettes, collected data on their approach to HCC and transplant oncology.RESULTS: After duplicates removal, 75 respondents were considered. Respondents from LT centers (n = 22, 29.3 %) were more in favor of LT in the case of HCC outside Milan criteria (90.9 % vs. 67.9 %, p = 0.037), recurrent HCC (95.5 % vs. 50.9 %, p = 0.002) and other malignancies such as cholangiocarcinoma or neuroendocrine tumors. No significant difference was observed concerning the proportion of centers favorable to LT for unresectable colorectal liver metastases (100 % vs. 88.7 %, p = 0.100).CONCLUSION: This national survey showed how management of HCC and awareness of transplant oncology may differ between HB and LT centers. Effective networking between HB and LT centers is crucial to provide optimal treatment and access to LT.
KW - Humans
KW - Liver Transplantation/statistics & numerical data
KW - Liver Neoplasms/surgery
KW - Carcinoma, Hepatocellular/surgery
KW - Surveys and Questionnaires
KW - Practice Patterns, Physicians'/statistics & numerical data
KW - Cholangiocarcinoma/surgery
KW - Male
KW - Neuroendocrine Tumors/surgery
KW - Female
KW - Health Care Surveys
U2 - 10.1016/j.dld.2024.09.007
DO - 10.1016/j.dld.2024.09.007
M3 - Original Article
C2 - 39379228
SN - 1590-8658
VL - 57
SP - 459
EP - 466
JO - DIGESTIVE AND LIVER DISEASE
JF - DIGESTIVE AND LIVER DISEASE
IS - 2
ER -